Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility
Seattle, April 30, 2021 (GLOBE NEWSWIRE) AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA® (pegloticase injection) – a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its state-of-the-art facility in Copenhagen, Denmark.
“We are extremely happy to further expand our strategic partnership with Horizon by leveraging the microbial capacity and expert team at our Copenhagen facility,” said AGC Biologics Chief Business Officer, Mark Womack. “We look forward to working closely with the Horizon team to further supply KRYSTEXXA to meet market demand.”
Germany
Japan
Milan
Lombardia
Italy
Denmark
Copenhagen
Køavn
Israel
Colorado
United-states
Boulder